• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Cheap drug protects against contrast-induced nephropathy


As the number of patients undergoing contrast-enhanced CT scans grows, so does the risk of contrast-induced nephropathy. How to protect patients? By asking them to pop an N-acetylcysteine (NAC) pill before the exam.

Principal investigator Dr. Aine M. Kelly and colleagues at the University of Michigan Medical School analyzed data from 41 studies that evaluated several kidney-protecting drugs. They found that patients who took NAC could avoid serious kidney damage caused by iodine-based contrast agents. The drug costs about 25¢ for a 500 mg dose and is available in most pharmacies. The investigators also found NAC outperforms other medicines used for the same purpose. Findings were published in the Feb. 19 issue of the Annals of Internal Medicine.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.